ADAG
Adagene Inc.
Price Chart
Latest Quote
$2.94
Current Price| Previous Close | $2.75 |
| Open | $2.72 |
| Day High | $3.16 |
| Day Low | $2.30 |
| Volume | 326,749 |
Stock Information
| Shares Outstanding | 47.13M |
| Total Debt | $6.85M |
| Cash Equivalents | $62.83M |
| Revenue | $103K |
| Net Income | $-29.89M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $138.57M |
| EPS (TTM) | $-0.64 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 13/42| Debt to Equity | 0.37 |
| Debt to Earnings | -0.55 |
| Current Ratio | 2.30 |
| Quick Ratio | 2.23 |
| Avg Revenue Growth | -24.75% |
| Profit Margin | -32386.45% |
| Return on Equity | -66.16% |
| Avg FCF Growth | -8.81% |
| FCF Yield | -21.46% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.94 | 326,749 |
| 2026-01-30 | $2.75 | 182,500 |
| 2026-01-29 | $2.91 | 226,500 |
| 2026-01-28 | $2.77 | 196,700 |
| 2026-01-27 | $2.49 | 147,700 |
| 2026-01-26 | $2.45 | 247,300 |
| 2026-01-23 | $2.49 | 1,994,200 |
| 2026-01-22 | $2.03 | 606,300 |
| 2026-01-21 | $1.69 | 34,300 |
| 2026-01-20 | $1.87 | 17,300 |
| 2026-01-16 | $1.96 | 53,800 |
| 2026-01-15 | $1.92 | 72,200 |
| 2026-01-14 | $1.80 | 45,600 |
| 2026-01-13 | $1.70 | 23,900 |
| 2026-01-12 | $1.59 | 156,800 |
| 2026-01-09 | $1.53 | 61,000 |
| 2026-01-08 | $1.65 | 61,300 |
| 2026-01-07 | $1.68 | 68,000 |
| 2026-01-06 | $1.82 | 32,100 |
| 2026-01-05 | $1.78 | 26,300 |
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
đ° Latest News
Penny Stocks To Watch In January 2026
Simply Wall St. âĸ 2026-01-19T12:05:09Z
3 Promising Penny Stocks With Market Caps Over $30M
Simply Wall St. âĸ 2025-12-19T18:05:17Z
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Zacks âĸ 2025-12-17T13:43:00Z
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires âĸ 2025-12-16T21:00:02ZAC Immune And 2 Other Promising Penny Stocks
Simply Wall St. âĸ 2025-10-31T12:05:17Z
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Zacks âĸ 2025-09-30T16:00:04Z
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Zacks âĸ 2025-09-25T13:40:01Z
Could Access to SAFEbody Technology Shift Exelixis (EXEL) Pipeline Strategy in Oncology?
Simply Wall St. âĸ 2025-09-18T11:27:59Z
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-09-08T20:59:36Z
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2025-08-21T13:40:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $103,204 | $18,111,491 | $9,292,724 | $10,175,258 |
| Operating Revenue | $103,204 | $18,111,491 | $9,292,724 | $10,175,258 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $851,874 | $1,107,820 | $693,323 | $363,762 |
| Total Expenses | $36,054,747 | $41,831,357 | $93,213,407 | $82,539,347 |
| Other Income Expense | $-439,592 | $3,289,639 | $4,723,713 | $1,175,363 |
| Other Non Operating Income Expenses | $466,620 | $1,843,437 | $2,168,388 | $1,778,822 |
| Net Non Operating Interest Income Expense | $2,949,471 | $3,175,265 | $-315,822 | $-287,596 |
| Interest Expense Non Operating | $851,874 | $1,107,820 | $693,323 | $363,762 |
| Operating Expense | $36,054,747 | $41,831,357 | $93,213,407 | $82,539,347 |
| General And Administrative Expense | $7,273,335 | $8,672,843 | $11,873,867 | $14,439,962 |
| Other Operating Expenses | - | $-3,480,632 | - | - |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,177,935 |
| Net Interest Income | $2,949,471 | $3,175,265 | $-315,822 | $-287,596 |
| Interest Income | $3,801,345 | $4,283,085 | $377,501 | $76,166 |
| Normalized Income | $-32,518,375 | $-20,031,022 | $-81,888,341 | $-72,725,341 |
| Net Income From Continuing And Discontinued Operation | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,177,935 |
| Total Operating Income As Reported | $-35,951,543 | $-23,719,866 | $-83,920,683 | $-72,364,089 |
| Net Income Common Stockholders | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,206,488 |
| Net Income | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,177,935 |
| Net Income Including Noncontrolling Interests | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,177,935 |
| Net Income Continuous Operations | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,177,935 |
| Pretax Income | $-33,441,664 | $-17,254,962 | $-79,512,792 | $-71,476,322 |
| Interest Income Non Operating | $3,801,345 | $4,283,085 | $377,501 | $76,166 |
| Operating Income | $-35,951,543 | $-23,719,866 | $-83,920,683 | $-72,364,089 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.74 | $-0.44 | $-1.85 | $-1.82 |
| Basic EPS | $-0.74 | $-0.44 | $-1.85 | $-1.82 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-476 | $361,550 | $638,831 | $-150,865 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-30,744,717 | $-16,384,886 | $-79,925,264 | $-69,384,069 |
| Total Unusual Items | $-906,212 | $1,446,202 | $2,555,325 | $-603,459 |
| Total Unusual Items Excluding Goodwill | $-906,212 | $1,446,202 | $2,555,325 | $-603,459 |
| Reconciled Depreciation | $938,861 | $1,208,458 | $1,449,530 | $1,125,032 |
| EBITDA (Bullshit earnings) | $-31,650,929 | $-14,938,684 | $-77,369,939 | $-69,987,528 |
| EBIT | $-32,589,790 | $-16,147,142 | $-78,819,469 | $-71,112,560 |
| Diluted Average Shares | $45,030,322 | $43,790,024 | $43,308,067 | $40,025,607 |
| Basic Average Shares | $45,030,322 | $43,790,024 | $43,308,067 | $40,025,607 |
| Diluted NI Availto Com Stockholders | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,206,488 |
| Tax Provision | $-17,553 | $1,691,408 | $459,055 | $1,701,613 |
| Gain On Sale Of Security | $-906,212 | $1,446,202 | $2,555,325 | $-603,459 |
| Research And Development | $28,781,412 | $36,639,146 | $81,339,540 | $68,099,385 |
| Selling General And Administration | $7,273,335 | $8,672,843 | $11,873,867 | $14,439,962 |
| Other Gand A | $7,273,335 | $8,672,843 | $11,873,867 | $14,439,962 |
| Otherunder Preferred Stock Dividend | - | $0 | $0 | $28,553 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $50,523,844 | $70,559,497 | $83,090,350 | $156,558,713 |
| Total Assets | $89,268,425 | $115,728,838 | $152,399,845 | $189,510,726 |
| Total Non Current Assets | $1,490,420 | $2,285,109 | $3,084,412 | $3,556,892 |
| Other Non Current Assets | $81,386 | $84,885 | $109,572 | $69,275 |
| Current Assets | $87,778,005 | $113,443,729 | $149,315,433 | $185,953,834 |
| Other Current Assets | $527,706 | $905,425 | $804,992 | $619,901 |
| Prepaid Assets | $2,047,488 | $2,382,020 | $4,132,331 | $3,436,020 |
| Receivables | $8,309 | $222,027 | $619,432 | $7,506,670 |
| Cash Cash Equivalents And Short Term Investments | $85,194,502 | $109,934,257 | $143,758,678 | $174,391,243 |
| Cash And Cash Equivalents | $85,194,502 | $109,934,257 | $143,758,678 | $174,391,243 |
| Accounts Receivable | - | - | $0 | $3,000,000 |
| Allowance For Doubtful Accounts Receivable | - | - | $0 | $0 |
| Gross Accounts Receivable | - | - | $0 | $3,000,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $18,493,539 | $22,306,871 | $27,971,231 | $7,489,374 |
| Long Term Debt And Capital Lease Obligation | $559,643 | $13,713,694 | $14,200,375 | $2,991,829 |
| Long Term Debt | $417,339 | $13,540,034 | $14,146,541 | $2,991,829 |
| Current Debt And Capital Lease Obligation | $17,933,896 | $8,593,177 | $13,770,856 | $4,497,545 |
| Current Debt | $17,792,555 | $8,397,222 | $13,618,873 | $4,497,545 |
| Other Current Borrowings | $12,923,599 | $4,161,549 | $2,850,128 | $1,376,319 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $38,744,581 | $45,169,341 | $69,309,495 | $32,952,013 |
| Total Non Current Liabilities Net Minority Interest | $559,643 | $13,713,694 | $14,229,093 | $3,130,099 |
| Current Liabilities | $38,184,938 | $31,455,647 | $55,080,402 | $29,821,914 |
| Other Current Liabilities | $56,265 | $119,749 | $111,915 | $143,060 |
| Payables And Accrued Expenses | $20,194,777 | $22,742,721 | $26,090,355 | $19,681,309 |
| Payables | $17,915,708 | $20,371,221 | $23,338,500 | $15,507,396 |
| Total Tax Payable | $485,969 | $563,143 | $349,039 | $1,719,720 |
| Income Tax Payable | $5,265 | $52,884 | $0 | $1,657,450 |
| Accounts Payable | $4,241,773 | $3,093,752 | $3,666,124 | $3,321,615 |
| Current Deferred Liabilities | - | $0 | $15,107,276 | $5,500,000 |
| Other Non Current Liabilities | - | - | $28,718 | $94,107 |
| Non Current Deferred Liabilities | - | - | $0 | $44,163 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $44,163 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $50,523,844 | $70,559,497 | $83,090,350 | $156,558,713 |
| Total Equity Gross Minority Interest | $50,523,844 | $70,559,497 | $83,090,350 | $156,558,713 |
| Stockholders Equity | $50,523,844 | $70,559,497 | $83,090,350 | $156,558,713 |
| Gains Losses Not Affecting Retained Earnings | $-526,903 | $-1,800,088 | $-849,305 | $-93,981 |
| Other Equity Adjustments | $-526,903 | $-1,800,088 | $-849,305 | $-93,981 |
| Retained Earnings | $-311,175,587 | $-277,751,476 | $-258,805,106 | $-178,833,259 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $0 | $1 | $1 | $94,074 |
| Ordinary Shares Number | $58,886,944 | $55,145,839 | $54,065,709 | $54,595,667 |
| Share Issued | $58,886,944 | $55,145,840 | $54,065,710 | $54,689,741 |
| Tangible Book Value | $50,523,844 | $70,559,497 | $83,090,350 | $156,558,713 |
| Invested Capital | $68,733,738 | $92,496,753 | $110,855,764 | $164,048,087 |
| Working Capital | $49,593,067 | $81,988,082 | $94,235,031 | $156,131,920 |
| Capital Lease Obligations | $283,645 | $369,615 | $205,817 | $0 |
| Total Capitalization | $50,941,183 | $84,099,531 | $97,236,891 | $159,550,542 |
| Treasury Stock | $0 | $4 | $4 | $619,605 |
| Additional Paid In Capital | $362,220,445 | $350,105,518 | $342,739,268 | $336,099,931 |
| Capital Stock | $5,889 | $5,547 | $5,497 | $5,627 |
| Common Stock | $5,889 | $5,547 | $5,497 | $5,627 |
| Long Term Capital Lease Obligation | $142,304 | $173,660 | $53,834 | $0 |
| Current Capital Lease Obligation | $141,341 | $195,955 | $151,983 | $0 |
| Line Of Credit | $4,868,956 | $4,235,673 | $10,768,745 | $3,121,226 |
| Current Accrued Expenses | $2,279,069 | $2,371,500 | $2,751,855 | $4,173,913 |
| Dueto Related Parties Current | $13,187,966 | $16,714,326 | $19,323,337 | $10,466,061 |
| Net PPE | $1,409,034 | $2,200,224 | $2,974,840 | $3,487,617 |
| Accumulated Depreciation | $-7,300,848 | $-6,708,077 | $-5,909,305 | $-5,322,264 |
| Gross PPE | $8,709,882 | $8,908,301 | $8,884,145 | $8,809,881 |
| Leases | $1,030,798 | $1,037,675 | $1,055,271 | $1,152,743 |
| Other Properties | $1,793,132 | $1,818,352 | $1,863,963 | $1,863,956 |
| Machinery Furniture Equipment | $5,602,307 | $5,687,171 | $5,773,034 | $5,793,182 |
| Buildings And Improvements | $283,645 | $365,103 | $191,877 | - |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $8,309 | $222,027 | $619,432 | $4,506,670 |
| Current Deferred Revenue | - | $0 | $15,107,276 | $5,500,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-29,734,565 | $-28,539,851 | $-49,302,625 | $-45,924,545 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-29,700,985 | $-28,454,839 | $-48,611,687 | $-43,414,619 |
| Cash Flow From Continuing Operating Activities | $-29,700,985 | $-28,454,839 | $-48,611,687 | $-43,414,619 |
| Operating Gains Losses | $908,685 | $-1,436,837 | $-2,548,514 | $622,432 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-33,580 | $-85,012 | $-690,938 | $-2,509,926 |
| Investing Cash Flow | $1,110,127 | $-77,356 | $-686,046 | $-2,509,926 |
| Cash Flow From Continuing Investing Activities | $1,110,127 | $-77,356 | $-686,046 | $-2,509,926 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $0 | $-3,976,681 | $-2,361,576 |
| Issuance Of Capital Stock | $7,331,019 | $0 | $0 | $149,793,232 |
| Financing Cash Flow | $3,769,220 | $-5,366,946 | $17,822,973 | $145,357,142 |
| Cash Flow From Continuing Financing Activities | $3,769,220 | $-5,366,946 | $17,822,973 | $145,357,142 |
| Net Other Financing Charges | $-315,557 | - | - | $-1,595,088 |
| Net Common Stock Issuance | $7,331,019 | $0 | $-3,976,681 | $147,431,656 |
| Common Stock Issuance | $7,331,019 | $0 | $0 | $149,793,232 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-8,342,510 | $-13,506,221 | $-4,353,588 | $-5,089,717 |
| Issuance Of Debt | $4,918,014 | $8,133,775 | $25,830,030 | $4,386,860 |
| Interest Paid Supplemental Data | $778,513 | $1,047,717 | $603,680 | $359,569 |
| Income Tax Paid Supplemental Data | $33,947 | $1,376,856 | $2,433,241 | - |
| End Cash Position | $85,194,502 | $109,934,257 | $143,758,678 | $174,391,243 |
| Beginning Cash Position | $109,934,257 | $143,758,678 | $174,391,243 | $75,150,998 |
| Effect Of Exchange Rate Changes | $81,883 | $74,720 | $842,195 | $-192,352 |
| Changes In Cash | $-24,821,638 | $-33,899,141 | $-31,474,760 | $99,432,597 |
| Proceeds From Stock Option Exercised | $178,254 | $5,500 | $323,212 | $223,431 |
| Common Stock Payments | $0 | $0 | $-3,976,681 | $-2,361,576 |
| Net Issuance Payments Of Debt | $-3,424,496 | $-5,372,446 | $21,476,442 | $-702,857 |
| Net Long Term Debt Issuance | $-3,424,496 | $-5,372,446 | $21,476,442 | $-702,857 |
| Long Term Debt Payments | $-8,342,510 | $-13,506,221 | $-4,353,588 | $-5,089,717 |
| Long Term Debt Issuance | $4,918,014 | $8,133,775 | $25,830,030 | $4,386,860 |
| Net Investment Purchase And Sale | $1,143,538 | $0 | $0 | $0 |
| Sale Of Investment | $129,643,538 | $47,000,000 | $0 | $0 |
| Purchase Of Investment | $-128,500,000 | $-47,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-33,411 | $-77,356 | $-686,046 | $-2,509,926 |
| Sale Of PPE | $169 | $7,656 | $4,892 | $0 |
| Purchase Of PPE | $-33,580 | $-85,012 | $-690,938 | $-2,509,926 |
| Change In Working Capital | $-1,890,455 | $-16,551,790 | $21,938,862 | $9,346,140 |
| Change In Other Current Liabilities | $-220,460 | $-265,784 | $-310,197 | $0 |
| Change In Other Current Assets | $3,499 | $24,687 | $-40,297 | $-24,210 |
| Change In Payables And Accrued Expense | $-2,611,447 | $-3,250,700 | $6,720,407 | $12,157,284 |
| Change In Accrued Expense | $-185,489 | $-122,201 | $-823,928 | $1,057,491 |
| Change In Payable | $-2,425,958 | $-3,128,499 | $7,544,335 | $11,099,793 |
| Change In Account Payable | $1,148,021 | $-572,372 | $344,509 | $1,511,640 |
| Change In Tax Payable | $-47,619 | $52,884 | $-1,657,450 | $1,657,450 |
| Change In Income Tax Payable | $-47,619 | $52,884 | $-1,657,450 | $1,657,450 |
| Change In Prepaid Assets | $724,235 | $1,649,878 | $-881,402 | $-231,287 |
| Change In Receivables | $213,718 | $397,405 | $6,887,238 | $-7,374,274 |
| Changes In Account Receivables | $0 | $0 | $3,000,000 | $-3,000,000 |
| Other Non Cash Items | $-1,143,538 | - | - | $-9,946 |
| Stock Based Compensation | $4,909,573 | $7,271,700 | $10,520,282 | $18,679,658 |
| Depreciation Amortization Depletion | $938,861 | $1,208,458 | $1,449,530 | $1,125,032 |
| Depreciation And Amortization | $938,861 | $1,208,458 | $1,449,530 | $1,125,032 |
| Depreciation | $938,861 | $1,208,458 | $1,449,530 | $1,125,032 |
| Net Foreign Currency Exchange Gain Loss | $906,212 | $-1,446,202 | $-2,555,325 | $603,459 |
| Gain Loss On Sale Of PPE | $2,473 | $9,365 | $6,811 | $18,973 |
| Net Income From Continuing Operations | $-33,424,111 | $-18,946,370 | $-79,971,847 | $-73,177,935 |
| Change In Other Working Capital | - | $-15,107,276 | $9,563,113 | $4,818,627 |